Vaccibody has received a $2.5 million grant from the Norwegian Research Council’s BIA Program to develop a therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company’s Vaccibody DNA vaccine platform, which targets antigen-presenting cells.   “We believe that there is a clear role for an easy-to-administer therapeutic vaccine and that our platform is the ‘missing link’ in DNA vaccines,” said Vaccibody chief executive officer Ole Henrik B...